corticotropin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4931 9002-60-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • corticotropin
  • ACTH
  • corticotrophin
  • adrenocorticotrophic hormone
  • acthar gel
  • cortrophin
  • corticotropin zinc hydroxide
  • corticotropin-zinc hydroxide
  • cortrophin-zinc
A hormone made in the pituitary gland. ACTH acts on the outer part of the adrenal gland to control its release of corticosteroid hormones. More ACTH is made during times of stress.
  • Molecular weight: 4541.14
  • Formula: C207H308N56O58S
  • CLOGP:
  • LIPINSKI: None
  • HAC: 114
  • HDO: 63
  • TPSA: 1836.25
  • ALOGS:
  • ROTB: 145

Drug dosage:

DoseUnitRoute
25 U P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 3, 1950 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 94.23 20.25 58 5007 42067 46638930
Injection site bruising 76.97 20.25 48 5017 35588 46645409
Infantile spasms 66.63 20.25 13 5052 250 46680747
Therapy cessation 57.81 20.25 36 5029 26593 46654404
Weight increased 46.58 20.25 72 4993 164401 46516596
Epidural lipomatosis 43.87 20.25 8 5057 105 46680892
Swelling face 41.48 20.25 39 5026 53020 46627977
Product dose omission issue 41.18 20.25 69 4996 168451 46512546
Blood glucose increased 39.99 20.25 44 5021 71969 46609028
Sarcoidosis 38.23 20.25 16 5049 5143 46675854
Fluid retention 33.32 20.25 34 5031 51012 46629985
Peripheral swelling 31.22 20.25 59 5006 158012 46522985
Visual impairment 29.08 20.25 36 5029 66653 46614344
Cushingoid 29.05 20.25 14 5051 6252 46674745
Swelling 23.98 20.25 46 5019 124465 46556532
Insomnia 23.67 20.25 54 5011 164870 46516127
Opsoclonus myoclonus 23.62 20.25 5 5060 146 46680851
Nail pigmentation 22.33 20.25 5 5060 191 46680806
Atonic seizures 21.02 20.25 6 5059 614 46680383

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infantile spasms 79.53 25.62 14 1755 285 29950424
Fluid retention 47.37 25.62 25 1744 24973 29925736
Blood glucose increased 39.30 25.62 31 1738 61499 29889210
Weight increased 37.97 25.62 33 1736 74880 29875829
Irritability 35.21 25.62 20 1749 23030 29927679
Drug ineffective 34.39 25.62 67 1702 340320 29610389
Insomnia 33.60 25.62 34 1735 93302 29857407
Intramyelinic oedema 32.18 25.62 4 1765 4 29950705
Hypertension 29.51 25.62 36 1733 121318 29829391
Injection site bruising 28.32 25.62 12 1757 7326 29943383
Therapy cessation 28.25 25.62 15 1754 15122 29935587
Nephrotic syndrome 25.71 25.62 11 1758 6874 29943835

Pharmacologic Action:

SourceCodeDescription
ATC H01AA01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
ACTH
FDA CS M0000499 Adrenocorticotropic Hormone
CHEBI has role CHEBI:33295 diagnostic aid
FDA EPC N0000175941 Adrenocorticotropic Hormone

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
West syndrome indication 28055006
Stevens-Johnson syndrome indication 73442001 DOID:0050426
Exacerbation of multiple sclerosis indication 192929006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.15 acidic
pKa2 3.37 acidic
pKa3 3.62 acidic
pKa4 3.86 acidic
pKa5 4.07 acidic
pKa6 4.31 acidic
pKa7 4.6 acidic
pKa8 9.43 acidic
pKa9 10.05 acidic
pKa10 12.25 acidic
pKa11 12.36 acidic
pKa12 12.63 acidic
pKa13 12.69 acidic
pKa14 12.93 acidic
pKa15 13.11 acidic
pKa16 13.11 acidic
pKa17 13.22 acidic
pKa18 13.41 acidic
pKa19 13.55 acidic
pKa20 13.6 acidic
pKa21 13.66 acidic
pKa22 13.75 acidic
pKa23 13.76 acidic
pKa24 13.79 acidic
pKa25 13.89 acidic
pKa26 14.0 acidic
pKa27 11.5 Basic
pKa28 11.26 Basic
pKa29 11.01 Basic
pKa30 10.81 Basic
pKa31 10.55 Basic
pKa32 10.3 Basic
pKa33 9.94 Basic
pKa34 7.62 Basic
pKa35 6.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Adrenocorticotropic hormone receptor GPCR AGONIST UNKNOWN IUPHAR
Melanocyte-stimulating hormone receptor GPCR AGONIST Ki 8.60 IUPHAR
Melanocortin receptor 3 GPCR AGONIST Ki 7.06 IUPHAR
Melanocortin receptor 4 GPCR AGONIST Ki 6.16 IUPHAR

External reference:

IDSource
D00146 KEGG_DRUG
4018523 VUID
N0000146845 NUI
12427-33-7 SECONDARY_CAS_RN
4018523 VANDF
4022410 VANDF
C0001655 UMLSCUI
CHEBI:3892 CHEBI
CHEMBL1201610 ChEMBL_ID
CHEMBL1201609 ChEMBL_ID
DB01285 DRUGBANK_ID
16132265 PUBCHEM_CID
3633 IUPHAR_LIGAND_ID
1366 INN_ID
471 INN_ID
K0U68Q2TXA UNII
376 RXNORM
2492 MMSL
326050 MMSL
4506 MMSL
4507 MMSL
84 MMSL
d00604 MMSL
002113 NDDF
002114 NDDF
126187000 SNOMEDCT_US
40789008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
1 Detoxification HUMAN OTC DRUG LABEL 81 55146-011 LIQUID 30 [hp_C] ORAL unapproved homeopathic 9 sections
Acthar HUMAN PRESCRIPTION DRUG LABEL 1 63004-8710 INJECTION 80 [USPU] INTRAMUSCULAR NDA 26 sections